u/FreeformSensei

This isn’t financial advice, simply my own opinion, so do your own DD. I own a long position in OMER ($12.47 average).

TLDR: OMER is trading around $870 million market cap. Their drug Yartemlea alone could give the company over a $5 billion market cap. Considering their $2.1 billion deal with NOVO for another drug in their pipeline, Zaltenibart, I think OMER is currently undervalued. I think OMER will be trading around $30 per share by the end of summer 2026. My bullish estimate is $40+ (with EMA approval, EU partnership, and stronger than anticipated Yartemlea sales in 2026)

OMER is one of my favorite biotech plays at the moment. They had their 1q 2026 earnings report on May 13th, and there is a lot to be excited about in regard to the future of OMER. Here are some highlights why I think this stock will be trading at a $2 billion market cap or more by the end of summer.

1. Yartemlea FDA & EMA Approval: OMER received FDA approval for their drug Yartemlea in December 2025, and was giving a broad label (can be used on patients as young as 2), with no warning label, They commercially launched the drug in late January 2026. The drug treats transplant-associated thrombotic microangiopathy (TA-TMA), and it is the only FDA drug approved to treat TA-TMA. On the recent earnings call, mgmt said that this drug has already achieved self-sustainability (sales revenue exceeds production, distribution, and sales team/marketing costs).

This drug alone will help the company become cash flow positive by 2027, using 2025 expenses (so the numbers could be different based on expenses in 2026), that means mgmt thinks Yartemlea will reach at least ~$123 million in annual revenue by 2027. That is only considering the US market. In it’s commercial launch quarter (1q 2026), Yartemlea achieved $9.9 million net sales, which beat analysts expectations of $4.19 million. By the end of March, Yartemlea had orders from 30 unique accounts; 60% of the top ten transplant centers in the US have given Yartemlea P&T committee approval. The U.S. Centers for Medicare and Medicaid Services (CMS) assigned a permanent health care common procedure coding system, J-code, which will go into effect on July 1st, 2026. The J-code designation will be a huge boost to reimbursement and help drive increased sale of Yartemlea from Medicare/Medicaid patients.

OMER is awaiting EU approval for Yartemlea, which will be decided in summer 2026. If Yartemlea gets EU approval, that will increase the patient population for Yartemlea by over 100%. On their earnings call in March, mgmt confirmed they are working on a partnership deal for the EU market. Based on mgmts estimate that Yartemlea could achieve over $120 million in revenue in the US alone by 2027, if they get EU approval, that could substantially increase their current estimate (and I personally think they are intentionally being conservative with their estimated sales). So Yartemlea alone could be reaching $250 million in annual revenue by 2027.

2. Yartemlea Sales Potential: As far as the sales potential for Yartemlea, data I’ve read says there about 2000-3000 new cases of TA-TMA each year in the US alone. There are some higher estimates all the way up to 10,000 a year, but I’ll stick with the 2000-3000 a year estimate. Yartemlea costs $36,000 per vial, and most patients need 8-10 doses for the treatment. So that would be $288,000 to $360,000 per patient. Let’s say there’s some discounts or rebates with clinics and/or health insurance companies, I’d conservatively say it’s about $250,000 per patient. If 100% of patients that develop TA-TMA were to get this drug, that would put the ceiling at $500 million to $750 million in sales per year, in the USA alone (using 2,000-3,000 patient estimate)

The EU market would be a big deal, and it would roughly double the patient population (4,000-6,000) annually. It would bring the potential ceiling to $1.0-$1.5 billion peak annual revenue for Yartemlea. If the number of patients each year is closer to the 10,000 estimate, then that would be $2.5 billion in peak annual revenue for Yartemlea.

I realize that 100% of patients getting Yartemlea isn’t realistic, but there is currently no other drug that has been approved to treat TA-TMA. There are some off-label drugs that have been used to treat TA-TMA but they have side effects (some have serious side effects). Yartemlea does not have any directly attributed side effects from OMERs research studies (infections have been seen, but that is extremely common with TA-TMA in general so no definitive relation to the drug itself). I think the low risk of side effects from Yartemlea and the ability to be used in children as young as 2, will make Yartemlea a heavily used drug in this population.

3. OMER Deal with NOVO: OMER secured a deal with NOVO Nordisk in November 2025 for another drug in their pipeline, Zaltenibart, which treats rare blood and kidney disorders. This deal is worth up to a potential $2.1 billion dollars. OMER received $240 million upfront in late 2025, which they used a portion of to pay off debt. They now only have $70.8 million in debt remaining in 2029 convertibles. OMER has $171.8 million in cash and investments on hand. They have an upcoming $100 million milestone payment from the NOVO deal that mgmt feels confident they will achieve (per the deal, no specifics given on what the milestone is), and I assume “upcoming” means it will happen at some point this year.

On the recent earnings call, the CFO highlighted that OMER had repurchased 360,000 shares for $4.2 million. They indicated they may repurchase more (no specifics given) shares depending on the market conditions. All in all I think OMER will be trading over $30 a share by late summer if it gets EU approval and sales of Yartemlea are looking strong. However, if OMER announces an EU partnership deal for Yartemlea in the summer and gets EMA approval, then I think OMER will be trading over $40 per share by the end of summer.

Disclaimer: This is not financial advice, do your own DD. I own a small long position in ONCO (0.38 average). This is a WSB type of stock, a true degenerates’ type of stock play.

Onconetix Inc (ONCO) is a small cap ($4.3 million) company with a high risk profile, but with a high reward potential due to a high amount of shorted shares (33%), low amount of time to cover, and high short fee (545%). I’ll start off by bringing up the set up, and I’ll finish by talking about the company profile and it’s upcoming reverse merger.

\*\*1. Shorted Shares Situation:\*\* There have been some reports showing ONCO has an ultra low share float (between 580,000-654,000 shares on the public float). There are discrepancies on the total shares due to a recent 1:5 reverse split this past March. However, it seems that the share float is closer to 10 million now, and that ONCO has diluted since the reverse split. There was a Seeking Alpha article published on May 4th, showing 33.03% of ONCO shares being shorted. The days to cover is very low (0.05-1.0 day to cover). According to Interactive Brokers, the short fee rate is 545.32%. While ONCO does not have as crazy of a short ratio and ultra low share float like some places are reporting, the opportunity for a rally is still there. ONCO could be a prime candidate to make huge movement due to the high percentage of shorted shares (33%), low days to cover (1 day), and high short fee rate (545%).

\*\*2. ONCO Company Profile:\*\* ONCO is a biotech company whose main product is Proclarix, and in vitro diagnostic test for prostate cancer. Proclarix is approved for sale in the EU. Two recent peer-reviewed studies supported Proclarix’ use to reduce unnecessary prostate biopsies. Revenue from Proclarix is extremely low, only about $21,457 in 1q of 2026. This week ONCO announced a US multi-center validation study (called PRIME) with Labcorp to enroll up to 500 men across multiple ethnicities. Comparable tests to Proclarix (4Kscore, PHI, ExoDx, and SelectMDx) generate revenue in the low-to-mid tens of millions annually, which is meaningful but not blockbuster type numbers. The biggest risk for this company is their financial profile. As of May 11th, ONCO has $4.1 million dollars cash, and their cash burn in 1q 2026 was $2.1 million. They will need to raise capital in the relatively near future (few months), not just to run the business, but to execute their deal with Realbotix.

\*\*3. Realbotix (XBOTF) Acquisition:\*\* The biggest catalyst for ONCO is their definitive agreement to acquire Realbotix, which was announced in February. Realbotix makes AI powered humanoid robots, and they’re in very early stages of commercial launch. Their first unit was delivered in April to Ericsson, and there last update highlighted they plan to deliver 19 humanoid robots by the end of May. They are also moving to a new facility in Las Vegas by June 2026, that will support higher unit output. The deal between ONCO and XBOTF is supposed to close in the second half of 2026. When the deal is executed. This is an all-stock acquisition. Realbotix will own 75%–90% of the combined company, which is expected to trade on Nasdaq. Realbotix (XBOTF) currently has a market cap of about $50.5 million. As a reminder, ONCO is trading at a $4.3 million market cap ($0.38 a share), so it is valued less than 10% of Realbotix’ current market cap. It is estimated that ONCO will need $12.5 million minimum net cash threshold, plus other conditions (committed equity line, conversion/amendment of existing securities). I only way I can see ONCO raising capital without dilution or loans would be to sell Proclarix, which could be a possibility. However, ONCO doesn’t have good leverage in a deal, considering their financial situation. ONCO has not mentioned selling Proclarix, so this is pure speculation.

Of the companies I’ve written DD reports here on Reddit so far, this is by far the highest risk stock. The financials do not look good for ONCO, which is why I say this is a degenerates stock and is absolutely a gamble. However, ONCO being valued at less than 10% of Realbotix’ $50.5 million market cap make me think ONCO is undervalued at this level. Since Realbotix will own 75-90% of shares after the deal, I think ONCO should currently be worth $5.05-$12.5 million market cap based on XBOTF market cap. That would be 20%-295% upside from its current value. The high level of shorted shares could cause ONCO stock to launch if a rally starts, but it would need to happen before more dilution comes, so time is of the essence.

Disclaimer: This is not financial advice, do your own DD. I own a small long position in ONCO (0.38 average). This is a WSB type of stock play, so it has high risk

Onconetix Inc (ONCO) is a small cap ($4.3 million) company with a high risk profile, but with a high reward potential due to a high amount of shorted shares (33%), low amount of time to cover, and high short fee (545%). I’ll start off by bringing up the set up, and I’ll finish by talking about the company profile and it’s upcoming reverse merger.

\*\*1. Shorted Shares Situation:\*\* There have been some reports showing ONCO has an ultra low share float (between 580,000-654,000 shares on the public float). There are discrepancies on the total shares due to a recent 1:5 reverse split this past March. However, it seems that the share float is closer to 10 million now, and that ONCO has diluted since the reverse split. There was a Seeking Alpha article published on May 4th, showing 33.03% of ONCO shares being shorted. The days to cover is very low (0.05-1.0 day to cover). According to Interactive Brokers, the short fee rate is 545.32%. While ONCO does not have as crazy of a short ratio and ultra low share float like some places are reporting, the opportunity for a rally is still there. ONCO could be a prime candidate to make huge movement due to the high percentage of shorted shares (33%), low days to cover (1 day), and high short fee rate (545%).

\*\*2. ONCO Company Profile:\*\* ONCO is a biotech company whose main product is Proclarix, and in vitro diagnostic test for prostate cancer. Proclarix is approved for sale in the EU. Two recent peer-reviewed studies supported Proclarix’ use to reduce unnecessary prostate biopsies. Revenue from Proclarix is extremely low, only about $21,457 in 1q of 2026. This week ONCO announced a US multi-center validation study (called PRIME) with Labcorp to enroll up to 500 men across multiple ethnicities. Comparable tests to Proclarix (4Kscore, PHI, ExoDx, and SelectMDx) generate revenue in the low-to-mid tens of millions annually, which is meaningful but not blockbuster type numbers. The biggest risk for this company is their financial profile. As of May 11th, ONCO has $4.1 million dollars cash, and their cash burn in 1q 2026 was $2.1 million. They will need to raise capital in the relatively near future (few months), not just to run the business, but to execute their deal with Realbotix.

\*\*3. Realbotix (XBOTF) Acquisition:\*\* The biggest catalyst for ONCO is their definitive agreement to acquire Realbotix, which was announced in February. Realbotix makes AI powered humanoid robots, and they’re in very early stages of commercial launch. Their first unit was delivered in April to Ericsson, and there last update highlighted they plan to deliver 19 humanoid robots by the end of May. They are also moving to a new facility in Las Vegas by June 2026, that will support higher unit output. The deal between ONCO and XBOTF is supposed to close in the second half of 2026. When the deal is executed. This is an all-stock acquisition. Realbotix will own 75%–90% of the combined company, which is expected to trade on Nasdaq. Realbotix (XBOTF) currently has a market cap of about $50.5 million. As a reminder, ONCO is trading at a $4.3 million market cap ($0.38 a share), so it is valued less than 10% of Realbotix’ current market cap. It is estimated that ONCO will need $12.5 million minimum net cash threshold, plus other conditions (committed equity line, conversion/amendment of existing securities). I only way I can see ONCO raising capital without dilution or loans would be to sell Proclarix, which could be a possibility. However, ONCO doesn’t have good leverage in a deal, considering their financial situation. ONCO has not mentioned selling Proclarix, so this is pure speculation.

Of the companies I’ve written DD reports here on Reddit so far, this is by far the highest risk stock. The financials do not look good for ONCO, which is why I say this is a degenerates stock and is absolutely a gamble. However, ONCO being valued at less than 10% of Realbotix’ $50.5 million market cap make me think ONCO is undervalued at this level. Since Realbotix will own 75-90% of shares after the deal, I think ONCO should currently be worth $5.05-$12.5 million market cap based on XBOTF market cap. That would be 20%-295% upside from its current value. The high level of shorted shares could cause ONCO stock to launch if a rally starts, but it would need to happen before more dilution comes, so time is of the essence.

Disclaimer: This is not financial advice, do your own DD. I own a small long position in ONCO (0.38 average). I wanted to coronate my first WSB post with a true degenerates’ type of stock play.

Onconetix Inc (ONCO) is a small cap ($4.3 million) company with a high risk profile, but with a high reward potential due to a high amount of shorted shares (33%), low amount of time to cover, and high short fee (545%). I’ll start off by bringing up the set up, and I’ll finish by talking about the company profile and it’s upcoming reverse merger.

**1. Shorted Shares Situation:** There have been some reports showing ONCO has an ultra low share float (between 580,000-654,000 shares on the public float). There are discrepancies on the total shares due to a recent 1:5 reverse split this past March. However, it seems that the share float is closer to 10 million now, and that ONCO has diluted since the reverse split. There was a Seeking Alpha article published on May 4th, showing 33.03% of ONCO shares being shorted. The days to cover is very low (0.05-1.0 day to cover). According to Interactive Brokers, the short fee rate is 545.32%. While ONCO does not have as crazy of a short ratio and ultra low share float like some places are reporting, the opportunity for a rally is still there. ONCO could be a prime candidate to make huge movement due to the high percentage of shorted shares (33%), low days to cover (1 day), and high short fee rate (545%).

**2. ONCO Company Profile:** ONCO is a biotech company whose main product is Proclarix, and in vitro diagnostic test for prostate cancer. Proclarix is approved for sale in the EU. Two recent peer-reviewed studies supported Proclarix’ use to reduce unnecessary prostate biopsies. Revenue from Proclarix is extremely low, only about $21,457 in 1q of 2026. This week ONCO announced a US multi-center validation study (called PRIME) with Labcorp to enroll up to 500 men across multiple ethnicities. Comparable tests to Proclarix (4Kscore, PHI, ExoDx, and SelectMDx) generate revenue in the low-to-mid tens of millions annually, which is meaningful but not blockbuster type numbers. The biggest risk for this company is their financial profile. As of May 11th, ONCO has $4.1 million dollars cash, and their cash burn in 1q 2026 was $2.1 million. They will need to raise capital in the relatively near future (few months), not just to run the business, but to execute their deal with Realbotix.

**3. Realbotix (XBOTF) Acquisition:** The biggest catalyst for ONCO is their definitive agreement to acquire Realbotix, which was announced in February. Realbotix makes AI powered humanoid robots, and they’re in very early stages of commercial launch. Their first unit was delivered in April to Ericsson, and there last update highlighted they plan to deliver 19 humanoid robots by the end of May. They are also moving to a new facility in Las Vegas by June 2026, that will support higher unit output. The deal between ONCO and XBOTF is supposed to close in the second half of 2026. When the deal is executed. This is an all-stock acquisition. Realbotix will own 75%–90% of the combined company, which is expected to trade on Nasdaq. Realbotix (XBOTF) currently has a market cap of about $50.5 million. As a reminder, ONCO is trading at a $4.3 million market cap ($0.38 a share), so it is valued less than 10% of Realbotix’ current market cap. It is estimated that ONCO will need $12.5 million minimum net cash threshold, plus other conditions (committed equity line, conversion/amendment of existing securities). I only way I can see ONCO raising capital without dilution or loans would be to sell Proclarix, which could be a possibility. However, ONCO doesn’t have good leverage in a deal, considering their financial situation. ONCO has not mentioned selling Proclarix, so this is pure speculation.

Of the companies I’ve written DD reports here on Reddit so far, this is by far the highest risk stock. The financials do not look good for ONCO, which is why I say this is a degenerates stock and is absolutely a gamble. However, ONCO being valued at less than 10% of Realbotix’ $50.5 million market cap make me think ONCO is undervalued at this level. Since Realbotix will own 75-90% of shares after the deal, I think ONCO should currently be worth $5.05-$12.5 million market cap based on XBOTF market cap. That would be 20%-295% upside from its current value. The high level of shorted shares could cause ONCO stock to launch if a rally starts, but it would need to happen before more dilution comes, so time is of the essence.

This is not financial advice, do your own DD. I own a small long position in ONCO. This is a Wall Street Bets type of stock I’m about to highlight, and is very high risk.

Onconetix Inc (ONCO) is a small cap ($4.3 million) company with a high risk profile, but with a high reward potential due to a low float, high amount of shorted shares, and low amount of time to cover. I’ll start off by bringing up the set up, and I’ll finish by talking about the company profile and it’s upcoming reverse merger.

**1. Short Squeeze Set Up:** There have been some reports showing ONCO has an ultra low share float (between 580,000-654,000 shares on the public float). There are discrepancies on the total shares due to a recent 1:5 reverse split this past March. However, it seems that the share float is closer to 10 million now, and that ONCO has diluted since the reverse split. There was a seeking Alpha article published on May 4th, showing 33.03% of ONCO shares being shorted. The days to cover is very low (0.05-1.0 day to cover). According to Interactive Brokers, the short fee rate is 545.32%. While ONCO does not have as crazy of a short ratio as some and ultra low share float like some places are reporting, the opportunity for a squeeze is still there. ONCO could be a prime candidate to make huge movement due to the high percentage of shorted shares (33%), low days to cover (1 day), and high short fee rate (545%).

**2. ONCO Company Profile:** ONCO is a biotech company whose main product is Proclarix, and in vitro diagnostic test for prostate cancer. Proclarix is approved for sale in the EU. Two recent peer-reviewed studies supported Proclarix’ use to reduce unnecessary prostate biopsies. Revenue from Proclarix is extremely low, only about $21,457 in 1q of 2026. This week ONCO announced a US multi-center validation study (called PRIME) with Labcorp to enroll up to 500 men across multiple ethnicities. Comparable tests to Proclarix (4Kscore, PHI, ExoDx, and SelectMDx) generate revenue in the low-to-mid tens of millions annually, which is meaningful but not blockbuster type numbers. The biggest risk for this company is their financial profile. As of May 11th, ONCO has $4.1 million dollars cash, and their cash burn in 1q 2026 was $2.1 million. They will need to raise capital in the relatively near future (few months), not just to run the business, but to execute their deal with Realbotix.

**3. Realbotix (XBOTF) Acquisition:** The biggest catalyst for ONCO is their definitive agreement to acquire Realbotix, which was announced in February. Realbotix makes AI powered humanoid robots, and they’re in very early stages of commercial launch. Their first unit was delivered in April to Ericsson, and there last update highlighted they plan to deliver 19 humanoid robots by the end of May. They are also moving to a new facility in Las Vegas by June 2026, that will support higher unit output. The deal between ONCO and XBOTF is supposed to close in the second half of 2026. When the deal is executed. This is an all-stock acquisition. Realbotix will own 75%–90% of the combined company, which is expected to trade on Nasdaq. Realbotix (XBOTF) currently has a market cap of about $50.5 million. As a reminder, ONCO is trading at a $4.3 million market cap ($0.38 a share), so it is valued less than 10% of Realbotix’ current market cap. It is estimated that ONCO will need $12.5 million minimum net cash threshold, plus other conditions (committed equity line, conversion/amendment of existing securities). I only way I can see ONCO raising capital without dilution or loans would be to sell Proclarix, which could be a possibility. However, ONCO doesn’t have good leverage in a deal, considering their financial situation. ONCO has not mentioned selling Proclarix, so this is pure speculation.

Of the companies I’ve written DD reports here on Reddit so far, this is by far the highest risk stock. The financials do not look good for ONCO, which is why I say this is a degenerates stock and certainly a gamble. However, ONCO being valued at less than 10% of Realbotix’ $50.5 million market cap make me think ONCO is undervalued at this level. Since Realbotix will own 75-90% of shares after the deal, I think ONCO should currently be worth $5.05-$12.5 million market cap based on XBOTF market cap. That would be 20%-295% upside from its current value. The high level of shorted shares could cause ONCO stock to launch if a rally starts, but it would need to happen before more dilution comes, so time is of the essence.

This is not financial advice, do your own DD. I own a small long position in ONCO (0.38 average). This is a Wall Street Bets type of stock I’m about to highlight, and is very high risk.

Onconetix Inc (ONCO) is a small cap ($4.3 million) company with a high risk profile, but with a high reward potential due to a low float, high amount of shorted shares, and low amount of time to cover. I’ll start off by bringing up the set up, and I’ll finish by talking about the company profile and it’s upcoming reverse merger.

1. Short Squeeze Set Up: There have been some reports showing ONCO has an ultra low share float (between 580,000-654,000 shares on the public float). There are discrepancies on the total shares due to a recent 1:5 reverse split this past March. However, it seems that the share float is closer to 10 million now, and that ONCO has diluted since the reverse split. There was a seeking Alpha article published on May 4th, showing 33.03% of ONCO shares being shorted. The days to cover is very low (0.05-1.0 day to cover). According to Interactive Brokers, the short fee rate is 545.32%. While ONCO does not have as crazy of a short ratio as some and ultra low share float like some places are reporting, the opportunity for a squeeze is still there. ONCO could be a prime candidate to make huge movement due to the high percentage of shorted shares (33%), low days to cover (1 day), and high short fee rate (545%).

2. ONCO Company Profile: ONCO is a biotech company whose main product is Proclarix, and in vitro diagnostic test for prostate cancer. Proclarix is approved for sale in the EU. Two recent peer-reviewed studies supported Proclarix’ use to reduce unnecessary prostate biopsies. Revenue from Proclarix is extremely low, only about $21,457 in 1q of 2026. This week ONCO announced a US multi-center validation study (called PRIME) with Labcorp to enroll up to 500 men across multiple ethnicities. Comparable tests to Proclarix (4Kscore, PHI, ExoDx, and SelectMDx) generate revenue in the low-to-mid tens of millions annually, which is meaningful but not blockbuster type numbers. The biggest risk for this company is their financial profile. As of May 11th, ONCO has $4.1 million dollars cash, and their cash burn in 1q 2026 was $2.1 million. They will need to raise capital in the relatively near future (few months), not just to run the business, but to execute their deal with Realbotix.

3. Realbotix (XBOTF) Acquisition: The biggest catalyst for ONCO is their definitive agreement to acquire Realbotix, which was announced in February. Realbotix makes AI powered humanoid robots, and they’re in very early stages of commercial launch. Their first unit was delivered in April to Ericsson, and there last update highlighted they plan to deliver 19 humanoid robots by the end of May. They are also moving to a new facility in Las Vegas by June 2026, that will support higher unit output. The deal between ONCO and XBOTF is supposed to close in the second half of 2026. When the deal is executed. This is an all-stock acquisition. Realbotix will own 75%–90% of the combined company, which is expected to trade on Nasdaq. Realbotix (XBOTF) currently has a market cap of about $50.5 million. As a reminder, ONCO is trading at a $4.3 million market cap ($0.38 a share), so it is valued less than 10% of Realbotix’ current market cap. It is estimated that ONCO will need $12.5 million minimum net cash threshold, plus other conditions (committed equity line, conversion/amendment of existing securities). I only way I can see ONCO raising capital without dilution or loans would be to sell Proclarix, which could be a possibility. However, ONCO doesn’t have good leverage in a deal, considering their financial situation. ONCO has not mentioned selling Proclarix, so this is pure speculation.

Of the companies I’ve written DD reports here on Reddit so far, this is by far the highest risk stock. The financials do not look good for ONCO, which is why I say this is a degenerates stock and certainly a gamble. However, ONCO being valued at less than 10% of Realbotix’ $50.5 million market cap make me think ONCO is undervalued at this level. Since Realbotix will own 75-90% of shares after the deal, I think ONCO should currently be worth $5.05-$12.5 million market cap based on XBOTF market cap. That would be 20%-295% upside from its current value. The high level of shorted shares could cause ONCO stock to launch if a rally starts, but it would need to happen before more dilution comes, so time is of the essence.